- Home
- GEVO vs PRQR Comparison
GEVO vs PRQR Comparison
Compare GEVO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- PRQR
- Stock Information
- Founded
- GEVO 2005
- PRQR 2012
- Country
- GEVO United States
- PRQR Netherlands
- Employees
- GEVO N/A
- PRQR N/A
- Industry
- GEVO Major Chemicals
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- PRQR Health Care
- Exchange
- GEVO Nasdaq
- PRQR Nasdaq
- Market Cap
- GEVO 246.8M
- PRQR 179.1M
- IPO Year
- GEVO 2011
- PRQR 2014
- Fundamental
- Price
- GEVO $1.32
- PRQR $2.04
- Analyst Decision
- GEVO Buy
- PRQR Strong Buy
- Analyst Count
- GEVO 2
- PRQR 8
- Target Price
- GEVO $7.58
- PRQR $8.88
- AVG Volume (30 Days)
- GEVO 5.1M
- PRQR 355.0K
- Earning Date
- GEVO 08-07-2025
- PRQR 08-07-2025
- Dividend Yield
- GEVO N/A
- PRQR N/A
- EPS Growth
- GEVO N/A
- PRQR N/A
- EPS
- GEVO N/A
- PRQR N/A
- Revenue
- GEVO $42,034,000.00
- PRQR $21,212,711.00
- Revenue This Year
- GEVO $1,022.79
- PRQR N/A
- Revenue Next Year
- GEVO $12.26
- PRQR N/A
- P/E Ratio
- GEVO N/A
- PRQR N/A
- Revenue Growth
- GEVO 145.38
- PRQR 85.91
- 52 Week Low
- GEVO $0.48
- PRQR $1.07
- 52 Week High
- GEVO $3.39
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- GEVO 55.45
- PRQR 71.54
- Support Level
- GEVO $1.17
- PRQR $1.89
- Resistance Level
- GEVO $1.41
- PRQR $2.20
- Average True Range (ATR)
- GEVO 0.09
- PRQR 0.11
- MACD
- GEVO 0.00
- PRQR 0.02
- Stochastic Oscillator
- GEVO 62.50
- PRQR 90.70
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.